MRNA Moderna Inc Total Asset Value of Company

MRNA (Moderna Corp) - company brandmark

Moderna, Inc. (MRNA) is a global biotechnology leader recognized for its innovative mRNA platforms used to combat viruses. This total asset value chart, serving as a valuation tool, shows a figure of 11487.42. Drug development here relies on AI algorithms and automated plants, while the current strategy focuses on overcoming pricing pressure when introducing new products into the US insurance sector.

MRNA (Moderna, Inc.) Company Total Assets history from 07/04/2022 to 10/29/2026

Analytical breakdowns and data insights for company Moderna Corp (MRNA)

- market value and analyst target forecast:
Stock Price modernatx.com|MRNA - Price Target Chart
- market capitalization data:
Market Valuation Moderna Therapeutics|MRNA - Enterprise Value
- issuer book value statistics:
Accounting Value of a Share Moderna|MRNA - Book Capitalization|Market Capitalization to Book Value Ratio modernatx.com|MRNA - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Moderna, Inc.|MRNA - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Moderna Therapeutics|MRNA - Company Aggregate Debts|Debts to Book Capitalization Moderna Therapeutics|MRNA - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Moderna|Interim Coverage Ratio modernatx.com
- net income and valuation multiples indicators:
MRNA - Company Net Income
Fundamental valuation:Moderna, Inc.
Manufactured products of Moderna, Inc.

Conservative capital demands absolute transparency of resource structure to assess business sustainability. This indicator measures the total value of assets via a reverse ROA calculation, determining the real basis of capital management. Moderna, Inc. (MRNA) aggressive investment in innovative therapies confirms the current value of 11487.42, reflecting the scale of R&D resources. Analyzing the total asset calculation allows for a comparison of the basis value against the management's long-term strategic goals.

Key competitors

summittxinc.com (SMMT) - Company Total Assets|Aggregate Company Assets Vaxcyte|Tarsus Pharmaceuticals Inc - Total Asset Value of Company|Company Total Assets CRMD|MCRB (Seres Therapeutics, Inc) - Aggregate Asset Value|Company Total Assets SPRO (Spero Therapeutics)|Company Total Assets SCYNEXIS Inc SCYX|ANTX - Aggregate Company Assets|Aggregate Asset Value PYPD (PolyPid Ltd.)|YS Biopharma (LSB) - Aggregate Company Assets|Cumulative Company Assets Iterum Therapeutics|PHGE (BiomX Inc) - Company Total Assets|Company Total Assets BioPharma Bio|Cumulative Company Assets SXTP (60 Degrees Pharmaceuticals)|OGEN (oragenics.com) - Aggregate Asset Value|Company Total Assets ONCO (Onconetix Corp)|Company Total Asset Base OpGen Corporation (OPGN)